MacroGenics: Melanoma trials
The registry lists 10 Melanoma studies with MacroGenics as lead sponsor. 1 are open to participants now and 3 have results posted.
Phase 1 9Phase 2 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of MGC026 in Participants With Advanced Solid TumorsRecruitingNCT06242470Phase 1
- A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsTerminatedNCT05551117Phase 2Results posted
- MGC018 With or Without MGA012 in Advanced Solid TumorsTerminatedNCT03729596Phase 1/2Results posted
- Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerCompletedNCT02475213Phase 1Results posted
- A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsCompletedNCT05293496Phase 1
- MGD019 DART® Protein in Unresectable/Metastatic CancerCompletedNCT03761017Phase 1
- Safety Study of MGD009 in B7-H3-expressing TumorsTerminatedNCT02628535Phase 1
- Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerCompletedNCT02381314Phase 1
- Tissue Procurement Substudy for Participants in Study CP-MGA271-01TerminatedNCT01918930Phase 1
- Safety Study of MGA271 in Refractory CancerCompletedNCT01391143Phase 1